REAL-TIME GLOBAL RESEARCH
Risk Reward Update
Research evidence excerpt
Not for redistribution without written consent of Morgan Stanley
M
Update
August 7, 2026 08:44 PM GMT
Charles River Laboratories International | North
America
Morgan Stanley & Co. LLC
Kallum L Titchmarsh
Equity Analyst
Risk Reward Update
What’s Changed
Updated Components
EPS
Bull Base Bear Scenarios
Risks to Price Target / Rating
Risk Reward for Charles River Laboratories International (CRL.N)
has been updated
Reason for change
Charles River Laboratories International (CRL.N, CRL UN)
Life Science Tools & Diagnostics | United States of
America
Stock Rating
Industry View
Price target
Shr price, close (Aug 6, 2026)
52-Week Range
Overweight
In-Line
$300.00
$265.51
$267.23-144.30
Fiscal Year Ending
12/25 12/26e 12/27e 12/28e
EPS ($)**
Prior EPS ($)**
10.29
11.34
12.90
14.22
Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare
framework
** = Based on consensus methodology
e = Morgan Stanley Research estimates
We updated our CRL model following Q2 2026 earnings results
Morgan Stanley does and seeks to do business with
companies covered in Morgan Stanley Research. As a result,
investors should be aware that the firm may have a conflict of
interest that could affect the objectivity of Morgan Stanley
Research. Investors should consider Morgan Stanley
Research as only a single factor in making their investment
decision.
The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.
Open report viewer